



New Drugs Acting on Ubiquitin-Proteasome System

Guest Editor:

Prof. Dr. Jorge A. R. Salvador

Laboratory of Pharmaceutical
Chemistry, Faculty of Pharmacy,
University of Coimbra, 3000-548
Coimbra, Portugal

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

UPS comprises a group of enzymes such as E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes), and E3 (ubiquitin-protein ligases) that tag proteins with the small-molecule ubiquitin (Ub), and the multi-subunit proteolytic complex, the 26S proteasome, a highly specific molecular device that degrades Ub-tagged substrate proteins into small molecular peptides involved in other biological functions. Deubiquitinases (DUBs) regulate biological processes associated with cell proliferation and apoptosis and are components of the UPS that catalyze the removal of ubiquitin moieties from target proteins or polyubiquitin chains, resulting in altered signaling or changes in protein stability. Ubiquitin-specific proteases (USPs) are the largest subfamily of DUBs. This Special Issue aims to provide an opportunity to share new findings and recent advances in UPS-targeted small molecules toward the development of new anticancer drugs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Contact Us

Molecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](#)